Liminatus Pharma, Inc. LIMN
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Liminatus Pharma, Inc. (LIMN) is a healthcare company listed in the US with a market value of about $4M.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -416%.
About Liminatus Pharma
Liminatus Pharma is listed in the US and classified in biotechnology: biological products (no diagnostic substances). It was profitable in 0 of the last 2 years in our data.
Score: 0.2 / 5
Checks passed
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 2 years
| Fiscal year | 2025 | 2024 |
|---|---|---|
| Revenue | — | — |
| Net income | -$10M | -$4M |
| Free cash flow | -$10M | — |
| EPS (diluted) | $-0.43 | $-0.20 |
| Net margin | — | — |
| ROIC | — | -415.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Liminatus Pharma pay a dividend?
Not currently.
Is Liminatus Pharma a good stock to buy?
We do not give buy or sell advice. Liminatus Pharma scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.